Kraton Receives Third ISCC PLUS Certification for Renewable Polymers
ReNew Series Enabling The Circular Economy
THE WOODLANDS, Texas, Feb. 10, 2025 /PRNewswire/ -- Kraton Corporation and Formosa Petrochemical Corporation are pleased to announce the ISCC PLUS certification of their HSBC Joint Venture plant in Mailiao, Taiwan. As the inventor of styrenic block copolymers (SBC), Kraton remains committed to delivering innovation and sustainable solutions for customers worldwide.
Kraton's Mailiao certification expands its portfolio of certified SBC manufacturing sites beyond Europe and North America into Asia. The Taiwan facility can now produce up to 100% ISCC PLUS-certified renewable SBC under the CirKular+™ ReNew Series, using the mass balance approach with ISCC PLUS- certified butadiene, styrene, and isoprene. This achievement strengthens Kraton's global presence, providing customers with unparalleled access to locally sourced, sustainable solutions across three key continents.
'The certification of the Mailiao facility underscores Kraton's dedication to advancing the circular economy and providing customers with sustainable, innovative solutions as the global industry leader,' shared Pedro Lopes, Kraton Global VP of Strategic Marketing, Product Management, and Supply Chain. 'Our well-established global monomer supplier network enables us to offer multiple solutions with up to 100% ISCC PLUS-certified content, tailored to customer needs for bio-circular, circular and bio-based waste. Kraton is committed to supporting the transition to renewable materials, reducing carbon emissions, and enabling a more sustainable future.'
The CirKular+ ReNew Series offers ISCC PLUS-certified renewable polymers, further expanding Kraton's existing suite of CirKular+ solutions designed to advance the circular economy. The ReNew Series offers a drop-in solution that reduces the cradle-to-gate carbon footprint* (including biogenic carbon) compared to fossil-based products. In addition to its differentiated portfolio of sustainable solutions, Kraton has an advanced in-house life cycle assessment (LCA) program and product carbon footprint modeling capabilities to support specific customer needs.
Launched in 2020, the CirKular+ Compatibilization Series and Performance Enhancement Series enable high-performance, innovative solutions for plastics upcycling and circular economy initiatives. CirKular+ helps customers transition to circular design with renewable and recycled feedstocks, improve product performance, and lower carbon footprint using a holistic approach to product lifecycle.
The ISCC PLUS certification at Kraton's Mailiao facility marks another exciting milestone in the company's sustainability journey. Kraton remains at the forefront of sustainable polymer innovation, leveraging its expertise and state-of-the-art manufacturing capabilities to create solutions that advance the circular economy.
* All relevant life cycle stages of the end-product must be considered to identify the overall life cycle impact along the value chain. Kraton Mailiao plant specific carbon footprint information is available upon request.
About Kraton Corporation
Kraton Corporation is a leading global producer of specialty polymers and high-value performance products derived from renewable resources. Kraton's polymers are used in a wide range of applications, including adhesives, coatings, consumer and personal care products, sealants, and lubricants, and medical, packaging, automotive, paving and roofing products. As the largest global provider in the pine chemicals industry, the company's pine-based specialty products are sold into adhesive, road and construction and tire markets, and it produces and sells a broad range of performance chemicals into markets that include fuel additives, oilfield chemicals, coatings, metalworking fluids and lubricants, inks, and mining. Kraton offers its products to a diverse customer base in over 70 countries worldwide.
*Kraton, the Kraton logo and design are all trademarks of Kraton Corporation, or its subsidiaries or affiliates, in one or more, but not all countries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Fasikl Receives FDA Clearance for Felix NeuroAI Wristband, the First and Only AI-Powered Treatment for Essential Tremor
MINNEAPOLIS--(BUSINESS WIRE)-- Fasikl, a trailblazing neuro-AI company redefining the intersection of advanced bioelectronic medicine and artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the first-of-its-kind Felix™ NeuroAI™ Wristband for tremor-related functional limitations in the upper limbs in adults with essential tremor. 'The Felix wristband represents a significant step forward in noninvasive, personalized treatment options for essential tremor,' said Rajesh Pahwa, M.D., Laverne and Joyce Rider Professor of Neurology at the University of Kansas School of Medicine, Director of the Movement Disorder Program at The University of Kansas Health System. 'For many patients, current treatment options fall short — pharmaceutical treatments are helpful for less than 50% of the patients, and deep brain stimulation and focused ultrasound, while effective, require surgical intervention. This new AI wearable wristband backed by clinical evidence is an effective treatment option in patients with essential tremor.' Essential tremor is the most common type of tremor disorder, affecting approximately 7 million people in the U.S., and is about seven times more common than Parkinson's disease. 1,2 It causes involuntary, rhythmic shaking, most often in the hands, which can make simple and everyday activities like drinking from a glass or tying shoelaces difficult. 3 Traditional treatment options are limited, with oral medications providing inconsistent relief and often accompanied by undesirable side effects. 4 Surgical interventions such as deep brain stimulation (DBS), while effective, require invasive procedures, carry surgical risks, and may not be suitable or desirable for all patients, particularly older adults or those with coexisting health conditions. 4 Unlike surgical or pharmacologic interventions, Felix is a noninvasive, wearable device that effortlessly connects to Fasikl's cloud-based AI platform, enabling continuous brain-AI co-adaptation and personalized therapy. Worn on the wrist, it uses the cloud to dynamically adjust stimulation, offering all-day symptom relief while seamlessly fitting into the wearer's lifestyle. The FDA clearance of Felix is supported by compelling data from the TRANQUIL study, a randomized, double-blind, sham-controlled trial that met its primary endpoint. Results showed that the Felix wristband significantly reduced tremors and displayed statistically and clinically significant improvement in the users' ability to perform daily activities compared to those using the sham device ('placebo effect'). Efficacy was consistent across demographics, with no serious device-related adverse events reported. Results were presented as Late-breaking Science at the American Academy of Neurology annual meeting in April 2025, reinforcing Felix's safety and potential as a first-of-its-kind, noninvasive, AI-powered treatment. 'FDA clearance of Felix marks a defining moment for Fasikl and the millions of people living with essential tremor who have long been underserved by existing therapies,' said Zhi Yang, Ph.D., CEO of Fasikl. 'This breakthrough in noninvasive, intelligent, and personalized neuromodulation marks the emergence of AI therapeutics in disease treatment. It offers a new option that is potentially more effective, safer, and more scalable. Our next step is to execute the commercialization plan to support Felix's initial product launch." The Felix NeuroAI Wristband will be available by prescription through healthcare providers in select U.S. regions starting in 2025, with nationwide availability expected in 2026. About Fasikl Based in Minneapolis, Fasikl, Inc. is a pioneering neuro-AI company dedicated to developing advanced, AI-powered neural technologies. A 2019 spin-off from the University of Minnesota, Fasikl leverages its proprietary platform to capture neural signals directly from peripheral nerves, enabling intelligent, adaptive therapy. The company is on a mission to transform the treatment landscape for movement disorders, paralysis, and other neurological impairments through cutting-edge neuromodulation innovations. Fasikl's portfolio includes the FDA-cleared Felix™ NeuroAI™ Wristband and the investigational Fasikl-X™ Nerve-Computer Interface. To learn more, visit References:
Yahoo
2 hours ago
- Yahoo
American Healthcare REIT Announces Dates for Second Quarter 2025 Earnings Release and Conference Call
IRVINE, Calif., July 1, 2025 /PRNewswire/ -- American Healthcare REIT, Inc. (the "Company") (NYSE: AHR) announced today that it will issue its second quarter 2025 earnings release on Thursday, August 7, 2025, after the close of trading. A public conference call with a simultaneous webcast will be held on Friday, August 8, 2025, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. During the conference call, company executives will review second quarter 2025 results, discuss recent events, and conduct a question-and-answer period. To join via webcast, investors may use the following link: To join the live telephone conference call, please dial one of the following numbers at least five minutes prior to the start time: North America Toll-Free: (800) 715-9871International Toll: +1 (646) 307-1963Conference ID: 2930459 A digital replay of the call will be available in the Investor Relations section of the Company's website at shortly after the conclusion of the call. The full text of the earnings report and supplemental data will be available immediately following the earnings release to the wire services on August 7, 2025, in the Investor Relations section of the Company's website at About American Healthcare REIT, Inc. American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns and operates a diversified portfolio of clinical healthcare real estate, focusing primarily on senior housing communities, skilled nursing, and outpatient medical buildings across the United States, and in the United Kingdom and the Isle of Man. Investor Contact: Alan PetersonVP, Investor Relations & Finance(949) 270-9200investorrelations@ Media Contact:Damon ElderSpotlight Marketing Communications(949) 427-1377damon@ View original content to download multimedia: SOURCE American Healthcare REIT, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Greenbrier announces Third Quarter financial results
LAKE OSWEGO, Ore., July 1, 2025 /PRNewswire/ -- The Greenbrier Companies, Inc. (NYSE:GBX) today announced its fiscal third quarter 2025 financial results through an earnings release that will be furnished with the Securities and Exchange Commission on a Form 8-K and available on its investor website at Greenbrier will host a live audio webcast at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), today, to discuss these financial results. The webcast and all the related materials can also be accessed through Greenbrier's Investor Relations website at About Greenbrier Greenbrier, headquartered in Lake Oswego, Oregon, is a leading international supplier of equipment and services to global freight transportation markets. Through its wholly-owned subsidiaries and joint ventures, Greenbrier designs, builds and markets freight railcars in North America, Europe and Brazil. We are a leading provider of freight railcar wheel services, parts, maintenance and retrofitting services in North America. Greenbrier owns a lease fleet of approximately 16,700 railcars that originate primarily from Greenbrier's manufacturing operations. Greenbrier offers railcar management, regulatory compliance services and leasing services to railroads and other railcar owners in North America. Learn more about Greenbrier at View original content: SOURCE The Greenbrier Companies, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
